Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
4519.T
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
+15%
50.57
vs 44
Q3.23
+14%
47.15
vs 41.21
Q4.23
-11%
55.43
vs 62.29
Q1.24
+1%
45.22
vs 44.68
Q2.24
+34%
67.98
vs 50.57
Q3.24
+41%
66.55
vs 47.15
Q4.24
-1%
54.8
vs 55.43
Q1.25
+25%
56.54
vs 45.22
Q2.25
+8%
73.49
vs 67.98
Q3.25
+3%
68.52
vs 66.55
Sales Growth
YoY
Current
Estimates
Q2.23
+14%
267.4B vs 235.6B
Q3.23
+14%
257.9B vs 225.3B
Q4.23
-38%
273.8B vs 438.5B
Q1.24
-24%
236.9B vs 312.2B
Q2.24
+18%
315.9B vs 267.4B
Q3.24
+22%
315.7B vs 257.9B
Q4.24
+10%
300.6B vs 273.8B
Q1.25
+22%
288.5B vs 236.9B
Q2.25
+0%
316.3B vs 315.9B
Q3.25
+1%
317.3B vs 315.7B
Return on Equity
QoQ
Q2.23
+5%
0.05
vs 0.05
Q3.23
+5%
0.05
vs 0.05
Q4.23
+6%
0.06
vs 0.05
Q1.24
+5%
0.05
vs 0.06
Q2.24
+6%
0.06
vs 0.05
Q3.24
+6%
0.06
vs 0.06
Q4.24
+5%
0.05
vs 0.06
Q1.25
+5%
0.05
vs 0.05
Institutionnal Ownership
Quote Panel
Key Metrics
Relative Strength
4519.T
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
JPX
89.00Â ( 1.26%)
Relative Strenght
Volume Buzz
-38%
Earning Acce
No
Dist 52w H.
18%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 4519.T compares to sector?
Forecast
337%2026-Revenue
371%2026-EPS
312%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available